conferenceseries.com
1086th Conference

Scientific Program

8TH ASIAN BIOLOGICS AND BIOSIMILARS CONGRESS

AUGUST 10-12, 2017 BEIJING, CHINA



Hosting Organization: Conference Series LLC
One Commerce Center-1201, Orange St. #600, Wilmington, Zip-19899, Delaware, USA
Ph: +1-702-508-5200, Fax: +1-650-618-1417, Toll free: +1-800-216-6499
Email: asianbiosimilars@pharmaceuticalconferences.com

Day 1 August 10, 2017

09:00-09:30 **Registrations**

Hall

conferenceseries.com **09:30-09:40** **Opening Ceremony**

Keynote Forum

09:40-09:45 **Introduction**

09:45-10:35 **Title: FDA/EMA current thinking on totality of evidence for development of biosimilars**
Kamali Chance, Vice President, Quintiles, IMS, USA

10:35-11:25 **Title: Strategic partnership for China biologics**
Jianguo Yang, President / CEO, Abpro China, USA

Group Photo

Networking & Refreshment Break: 11:25-11:50

11:50-12:40 **Title: Biosimilars: Accelerating early clinical development**
Raymond Huml, Vice Precident, Quintiles IMS, USA

Lunch Break: 12:40-13:40

Sessions:
Challenges in Developing Biosimilars | Cost Analysis of Biosimilars | Emerging Trends in Biosimilars | Emerging Biosimilars in Therapeutics

Session Introduction

Session Chair: Darius Panaligan, Vice President, Global Head of Commercial at Merck Group, Switzerland

Session Co-Chair: Hossein Pakdaman, President of Iranian Neurological Association, Iran

13:40-14:10 **Title: Challenges in assessing therapeutic equivalence of nano-similars**
Beat Fluehmann, Director Vifor Pharma Ltd, Switzerland

14:10-14:40 **Title: Challenges and opportunities in biosimilar commercialization**
Darius Panaligan, Vice President, Global Head of Commercial at Merck Group, Merck Biosimilars, Switzerland

14:40-15:10 **Title: Convergence of regulatory expectations**
Robert Salcedo, President and Founder at Biosimilars Solutions and BioSciencesCorp, USA

Networking & Refreshment Break: 15:10-15:30

15:30-16:00 **Title: From neuromodulation to drug discovery and treatment**
Luis Ulloa, Professor of Surgery, Rutgers University- New Jersey Medical School, USA

16:00-16:30 **Title: The role of regulatory policies in relation to the local biosimilars production**
Gustavo H Marin, Head Professor at UNLP-CONICET, Argentina

Day 1 Ends

Day 2 August 11, 2017

Hall

Keynote Forum

10:00-10:05 **Introduction**

10:05-10:55 **Title: Strategy for the global development of biosimilars: Putting it's all together**
Oxana Iliach, Sr. Director Quintiles IMS, Canada

Networking & Refreshment Break: 10:55-11:25

11:25-12:15 **Title: Clinical development of biosimilars for Western markets: Planning for success**
Charu Manaktala, Senior Medical Director Quintiles IMS, India

Lunch Break: 12:15-13:15

Sessions:
Globalization of Biosimilars | Biosimilars Market Challenges & Prospects | Pharmacovigilance of Biosimilars

Session Introduction

Session Chair: Robert Salcedo, President and Founder at Biosimilars Solutions and BioSciencesCorp, USA

Session Co-Chair: Hossein Pakdaman, President of Iranian Neurological Association, Iran

13:15-13:45 **Title: 10 year perspective: science and commercial power. Battle of the giants in biosimilars**
Richard Littlewood, CEO Founder at appliedstrategic, London, UK

13:45-14:15	**Title: Biosimilars in the UK's NHS: Attitudes, appetites and acceptance** **Divya Chadha Manek**, Head of Commercial Business Development, NHR, UK
14:15-14:45	**Title: Comparison of biosimilar registration guidelines between EU and USA** **Frank Cheng**, Founder and principle senior consultant, Alban Pharma, Hong Kong

Special Session

14:45-15:25	**Title: Biosimilars: Challenges in safety and risk management** **Asif Mahmood**, Disease Area Cluster Lead for Biosimilars Pfizer, USA

Networking & Refreshment Break: 15:25-15:55

Poster Presentation @ 15:55-16:35

BS-01	**Title: Theodor bilharz research institute therapeutic products and health tools** **Ismaeil Saad**, Professor, Theodor Bilharz Research Institute (TBRI), Giza
BS-02	**Title: Some considerations about biosimlar safety** **Samer M Al-Hulu**, PhD, Al-Qasim Green University, Iraq
BS-03	**Title: Biosimilars: Overview, evolution and regulations assessment systematic development, regulations and molecules approved in Australia, Brazil, Malaysia, Japan, Singapore and South Korea** **Tomas Gabriel BAS**, PhD, Coquimbo, Chile

Day 2 Ends

Day 3 August 12, 2017

Hall

Keynote Forum

10:00-10:05	**Introduction**
10:05-10:55	**Title: Biosimilars in treatment of multiple sclerosis** **Hossein Pakdaman**, President of Iranian Neurological Association, Iran

Sessions:

Emerging Biosimilars in Therapeutics | Clinical Studies on Biosimilars

Session Introduction

11:20-11:50	**Title: Practical considerations in clinical strategy to support the development of biologics device combination products** **Zhaoyang Li**, Director Sanofi
11:50-12:20	**Title: Expression of shiga-like toxin fused to vascular endothelial growth factor in *E.coli* for targeting angiogenesis** **Osama O Ibrahim**, Consultant Biotechnology/ Food Safety Bioinnovation, USA

Lunch Break: 12:00-13:00

Networking and Closing Ceremony

